ArticleOncology research2025

Isoliquiritigenin Inhibits Triple-Negative Breast Cancer Progression via Targeting the IRF5/SLC7A5/IDO1-Mediated Tryptophan Metabolism Pathway.

Sihai Duan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.